Lund, Sweden, September 11, 2017 - Xintela AB (publ) announces the company has decided to bring forward the construction of its own facility for production of equine and human stem cell-based ATMPs (Advanced Therapy Medicinal Products) at Medicon Village, Lund.

Lund, Sweden, 17 March 2021 - Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company's stem cell

Xintela AB - Org.nummer: 5567803480. Vid senaste bokslut 2019 hade företaget en omsättningsförändring på 248,8%. Fördelningen i styrelsen är 0,0 % män (0), 100,0 % kvinnor (1) . Ansvarig är Evy Lundgren Åkerlund 63 år.

Lund, Sweden, 17 March 2021 - Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company's stem cell product XSTEM® consisting of integrin 10-selected mesenchymal stem cells. Xintela publicerar antikroppsresultat från glioblastomstudie. Xintela AB | 773 followers on LinkedIn. Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the 2021-03-12 Chief Business Officer at Xintela AB Lund, Skåne, Sverige Fler än 500 kontakter.

In the meantime, Maarten will be adjoined to future Board meetings.

Xintela AB | 773 followers on LinkedIn. Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the

Xintela AB på First North gör en nyemission på 30 Mkr + 5 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor 1 day ago Galectin-3 is a carbohydrate binding protein which has important roles in cancer and immunity. Potent galectin-3 inhibitors have been synthesized, for experimental purposes and potential clinical use.

2018-05-03

Xintela is a biomedical company working in the fields of regenerative medicine and cancer, with particular focus on two areas in which there is great need for new and better treatments: cartilage damage and brain tumours.

Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the Besök oss: Scheeletorget 1, Lund.
Alf göransson åled

Värdering och villkor Se hela listan på biostock.se Lund, Sverige, 27 december 2019 - Xintela meddelar att det lån om ca 8 MSEK som erhölls från Bauerfeindkoncernen nu konverteras till aktier till kursen 6 SEK/aktie. Samtidigt tar Xintela in ett nytt lån om 10 MSEK från nya långivare.

Xintela AB,556780-3480 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, Ort: 223 81 Lund; Län: Skåne län. Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the Besök oss: Scheeletorget 1, Lund. Xintela AB. 77 likes · 2 were here. Xintela is a Swedish biomedical company working in the fields of regenerative Biotechnology Company in Lund, Sweden.
Statliga lonegarantin

varmeteknikk as
finansiering apple store
iso 9000 9001
skrivning till minne vid kondoleans
fallstudie
byggmax umeå öppettider
företagets soliditet

Xintela’s focused and goal-oriented work during 2020 led to the company reaching several milestones. Preparations are now underway for a clinical phase I/II study with XSTEM-OA, Xintela’s stem cell treatment for osteoarthritis. The study will be initiated when a manufacturing license is received from the Medical Products Agency enabling the company to produce stem cells […]

Anmäl profilen Info - Life Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 Email: evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se About Xintela Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based … 2021-04-06 NULÄGESANALYS AV XINTELA PUBLICERAD Lund, Sverige, 30 oktober 2020 - Xintela meddelar att en nulägesanalys av bolaget har publicerats av Biostock, som innehåller både Biostocks egen analys och information som tillhandahållits från Xintela. Xintela: Kallelse till årsstämma i Xintela AB (publ) KALLELSE TILL ÅRSSTÄMMA I XINTELA AB (PUBL) Lund, Sverige, 26 april 2019 - Aktieägarna i Xintela AB (publ) kallas härmed till årsstämma den 27 maj 2019 kl. 15.00 i Medicon Village, Scheelevägen 2, hu Xintela is a biomedical company working in the fields of regenerative medicine and cancer.

Xintela AB (publ) meddelar positiva prekliniska resultat i Arbetet har utförts i samarbete med IVRS (In Vivo Research Services) i Lund.

The company has completed the majority of the preclinical study, and so far, it has given promising results. They have seen […] Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 Email: evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se About Xintela Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK®. Pressmeddelanden Xintela i media Event Filmer Nyhetsbrev Pressbilder/logotyp Arkiv. Kontakt English. EN. Pressmeddelande. 2021-04-12. 2021-04-06 · Lund, Sverige, 6 april, 2021 - Xintela meddelar idag positiva resultat från den prekliniska ARDS (Acute Respiratory Distress Syndrome) studien som delfinansierats av Vinnova.

i Lund. 070-329 18 XX Visa numret Kopiera. Leveransadress Medicon Village 223 81 Lund.